SURF -Bullish Divergence Found On RSI - Possible Gains

Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.

SHORT INTEREST
158.09K 08/15/19

P/E Current
-5.60

P/E Ratio (with extraordinary items)
-1.17

Average Recommendation: OVERWEIGHT

Average Target Price: 10.50